FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease
A legfontosabb adatok
- Hol
- Rochester (Egyesült Államok)A helyszín megnézése
- Fázis
- Korai 1. fázis
Helyszínek itt: Egyesült Államok
- Mayo Clinic in RochesterRochester, Egyesült ÁllamokContact: Casey R. McAdam, CCRPRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Mayo Clinic
- Azonosító
- NCT07460232
- A regiszteradat frissítve
- 2026. október 30.
- Eredeti leírás
The purpose of this research is to evaluate the performance [sensitivity, specificity, accuracy] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.A teljes eredeti leírásKevesebb
18Fluoro-O-(2) Fluoroethyl-L-tyrosine (FET) PET For Localization Of Pituitary Adenomas In Patients With Cushing Disease
The purpose of this research is to evaluate the performance [sensitivity, specificity, accuracy] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
Bevonási feltételek: Patients must meet ALL criteria listed below for entry:; Biochemically diagnosed ACTH-dependent Cushing disease; No previous pituitary surgery; Planned to undergo pituitary surgery for localization/resection of adenoma; No contraindications for PET/CT; Recent (within 3 months) pituitary MR, or pending pituitary MR to be performed as close as possible to FET PET/CT; Age ≥ 18 years; Ability to provide informed consent.
Kizáró feltételek: Need for emergent surgery that would be delayed by participation; Patients receiving any other investigational agent within the past 28 days; Bacterial, viral, or fungal infections requiring systemic therapy; Serious co-morbidities and serious nonmalignant disease (e.g., hydronephrosis, kidney failure, liver failure, systemic or local inflammatory or autoimmune diseases or other conditions) that in the opinion of the investigator could compromise patient safety and/or protocol objectives; Known diagnosis of autoimmune disorders; Known hypersensitivity to any excipients used in FET; Pregnant as determined by a pregnancy test as per institutional guidelines for individuals of child-bearing potential; Declining to use effective contraceptive methods during the study (for individuals of child-bearing potential); Breastfeeding. Note: nursing parents are allowed if the potential participant commits to pumping breast milk and discarding it from injection to ≥ 24 hours from the time of the FET injection.